HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Limbal stem cell deficiency and ocular phenotype in ectrodactyly-ectodermal dysplasia-clefting syndrome caused by p63 mutations.

AbstractOBJECTIVE:
To describe the ocular phenotype in patients with ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome (MIM#604292) and to determine the pathogenic basis of visual morbidity.
DESIGN:
Retrospective case series.
PARTICIPANTS:
Nineteen families (23 patients) affected by EEC syndrome from the United Kingdom, Ireland, and Italy.
METHODS:
General medical examination to fulfill the diagnostic criteria for EEC syndrome and determine the phenotypic severity. Mutational analysis of p63 was performed by polymerase chain reaction-based bidirectional Sanger sequencing. All patients with EEC syndrome underwent a complete ophthalmic examination and ocular surface assessment. Limbal stem cell deficiency (LSCD) was diagnosed clinically on the basis of corneal conjunctivalization and anatomy of the limbal palisades of Vogt. Impression cytology using immunofluorescent antibodies was performed in 1 individual. Histologic and immunohistochemical analyses were performed on a corneal button and corneal pannus from 2 EEC patients.
MAIN OUTCOME MEASURES:
The EEC syndrome phenotypic severity (EEC score), best-corrected Snellen visual acuity (decimal fraction), slit-lamp biomicroscopy, tear function index, tear breakup time, LSCD, p63 DNA sequence variants, impression cytology, and corneal histopathology.
RESULTS:
Eleven heterozygous missense mutations in the DNA binding domain of p63 were identified in all patients with EEC syndrome. All patients had ocular involvement and the commonest was an anomaly of the meibomian glands and lacrimal drainage system defects. The major cause of visual morbidity was progressive LSCD, which was detected in 61% (14/23). Limbal stem cell deficiency was related to advancing age and caused a progressive keratopathy, resulting in a dense vascularized corneal pannus, and eventually leading to visual impairment. Histologic analysis and impression cytology confirmed LSCD.
CONCLUSIONS:
Heterozygous p63 mutations cause the EEC syndrome and result in visual impairment owing to progressive LSCD. There was no relationship of limbal stem cell failure with the severity of EEC syndrome, as classified by the EEC score, or the underlying molecular defect in p63.
FINANCIAL DISCLOSURE(S):
The authors have no proprietary or commercial interest in any of the materials discussed in this article.
AuthorsEnzo Di Iorio, Stephen B Kaye, Diego Ponzin, Vanessa Barbaro, Stefano Ferrari, Elisabetta Böhm, Paola Nardiello, Giuseppe Castaldo, John A McGrath, Colin E Willoughby
JournalOphthalmology (Ophthalmology) Vol. 119 Issue 1 Pg. 74-83 (Jan 2012) ISSN: 1549-4713 [Electronic] United States
PMID21959367 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • TP63 protein, human
  • Transcription Factors
  • Tumor Suppressor Proteins
Topics
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Cleft Lip (diagnosis, genetics)
  • Cleft Palate (diagnosis, genetics)
  • Corneal Diseases (diagnosis, genetics, surgery)
  • DNA Mutational Analysis
  • Ectodermal Dysplasia (diagnosis, genetics)
  • Epithelial Cells (pathology)
  • Epithelium, Corneal (pathology)
  • Fluorescent Antibody Technique, Indirect
  • Humans
  • Keratoplasty, Penetrating
  • Limbus Corneae (pathology)
  • Male
  • Middle Aged
  • Mutation, Missense
  • Phenotype
  • Polymerase Chain Reaction
  • Retrospective Studies
  • Stem Cells (pathology)
  • Transcription Factors (genetics)
  • Tumor Suppressor Proteins (genetics)
  • Vision Disorders (genetics)
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: